UNSPSC 51332869: Pipotiazine undecylenate

This classification denotes an antipsychotic agent C35H51N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XL1XX5J17, chemically known as 10-undecenoic acid,2-(1-(3-(2-((dimethylamino)sulfonyl)-10h-phenothiazin-10-yl)propyl)-4-piperidinyl)ethyl ester, but more generally known as pipotiazine undecylenate, which bears US NIH Compound Identifier 89615. European Medicines Agency schedules Pipotiazine undecylenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03861MIG.

Most nations, for tariff and trade purposes, schedule pipotiazine undecylenate under HS 29350090 and SITC 51580. As of Q4 2014, PIPOTIAZINE UNDECYLENATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)S(=O)(=O)C1CCC2C(C1)N(C3CCCCC3S2)CCCN4CCC(CC4)CCOC(=O)CCCCCCCCC=C.

UNSPSC 51332869 Pipotiazine undecylenate is a Commodity code that in recent state and local procurement activity appears to cover pharmaceutical products and related health-system supplies, though the single recent opportunity posted under this code does not involve pipotiazine itself. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS, suggesting the code may be used more broadly to classify emergency-response pharmaceuticals and harm-reduction equipment rather than the specific compound named in the code definition. State and local buyers under this code include county health departments and community health agencies focused on overdose response and substance-abuse mitigation.

Seminole County, Florida represents the only recent documented activity under this code. The county issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 (note: the due date in the record predates the posting date, indicating a data discrepancy in the source). The contract included a two-year initial term with an optional one-year renewal, fixed-fee pricing structure, E-Verify compliance, and potential FEMA funding with associated federal regulatory requirements. No explicit set-asides for disadvantaged enterprises were designated. The mismatch between the code's nominal substance and the actual naloxone procurement reflects the common state and local practice of using pharmaceutical-family codes to classify a range of emergency-response and public-health products beyond their narrow technical names.